The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature

Oncotarget

Volumn 6, Issue 31, 2015, Pages 31613-31627

  Díaz Beyá, Marina ^a,b   Brunet, Salut ^b,c   Nomdedéu, Josep ^b,c   Pratcorona, Marta ^a,b   Cordeiro, Anna ^d   Gallardo, David ^e   Escoda, Lourdes ^f   Tormo, Mar ^g   Heras, Inmaculada ^h   Ribera, Josep Maria ^b,i   Duarte, Rafael ^j   de Llano, María Paz Queipo ^k   Bargay, Joan ^l   Sampol, Antonia ^m   Nomdedeu, Meritxell ^a   Risueño, Ruth M ^b   Hoyos, Montserrat ^c   Sierra, Jorge ^b,c   Monzo, Mariano ^d   Navarro, Alfons ^d   Esteve, Jordi ^a,b,d   more..

^a HOSPITAL CLÍNIC   (Spain)

^b JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE IJC   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h HOSPITAL MORALES MESEGUER   (Spain)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^j HOSPITAL DURAN I REYNALS   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^l HOSPITAL SON LLÀTZER   (Spain)

^m HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

more..

Author keywords

AML; HOTAIRM; HOX; lincRNA; LncRNA

Indexed keywords

CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HOX ANTISENSE INTERGENIC RNA MYELOID 1; IDARUBICIN; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 196B; MITOXANTRONE; NUCLEOPHOSMIN; UNCLASSIFIED DRUG; HOMEODOMAIN PROTEIN; HOXA PROTEIN; LONG NON-CODING RNA HOTAIRM1, HUMAN; MIRN196 MICRORNA, HUMAN; NUCLEAR PROTEIN; TUMOR MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DISEASE FREE SURVIVAL; FEMALE; GENE; GENE MUTATION; GENE OVEREXPRESSION; HIGH RISK PATIENT; HOX GENE; HUMAN; INCIDENCE; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; NPM1 GENE; OVERALL SURVIVAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RISK ASSESSMENT; CHI SQUARE DISTRIBUTION; CHROMOSOME ANALYSIS; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MUTATION; ODDS RATIO; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; CHI-SQUARE DISTRIBUTION; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HOMEODOMAIN PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NUCLEAR PROTEINS; ODDS RATIO; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; RNA, LONG NONCODING; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84945568293     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5148     Document Type: Article

References (53)

1. Döhner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115:453-474.
2. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116:354-365.
3. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, Habdank M, Spath D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Dohner H. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358:1909-1918.
4. Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu Y-Z, Mrózek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. Journal of clinical oncology. 2013; 31:2086-2093.
5. Diaz-Beya M, Navarro A, Ferrer G, Diaz T, Gel B, Camos M, Pratcorona M, Torrebadell M, Rozman M, Colomer D, Monzo M, Esteve J. Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene. Leukemia. 2012.
6. Diaz-Beya M, Brunet S, Nomdedeu J, Tejero R, Díaz T, Pratcorona M, Tormo M, Ribera JM, Escoda L, Duarte R. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia. 2014; 28:804-812.
7. Schwind S, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Whitman SP, Hickey C, Becker H, Metzeler KH. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of clinical oncology. 2010; 28:5257-5264.
8. Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrózek K, Bucci D, Carroll AJ, Baer MR. Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proceedings of the National Academy of Sciences. 2014; 111:18679-18684.
9. Magli MC, Barba P, Celetti A, De Vita G, Cillo C, Boncinelli E. Coordinate regulation of HOX genes in human hematopoietic cells. Proceedings of the National Academy of Sciences. 1991; 88:6348-6352.
10. Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Molecular and Cellular Biology. 2001; 21:224-234.
11. Bach C, Buhl S, Mueller D, García-Cuéllar M-P, Maethner E, Slany RK. Leukemogenic transformation by HOXA cluster genes. Blood. 2010; 115:2910-2918.
12. Argiropoulos B, Humphries R. Hox genes in hematopoiesis and leukemogenesis. Oncogene. 2007; 26:6766-6776.
13. Drabkin H, Parsy C, Ferguson K, Guilhot F, Lacotte L, Roy L, Zeng C, Baron A, Hunger S, Varella-Garcia M. Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia. 2002; 16:186-195.
14. Andreeff M, Ruvolo V, Gadgil S, Zeng C, Coombes K, Chen W, Kornblau S, Baron A, Drabkin H. HOX expression patterns identify a common signature for favorable AML. Leukemia. 2008; 22:2041-2047.
15. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999; 286:531-537.
16. Spencer DH, Young MA, Lamprecht TL, Helton NM, Fulton R, O'Laughlin M, Fronick C, Magrini V, Demeter RT, Miller CA, Klco JM, Wilson RK, Ley TJ. Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells. Leukemia. 2015.
17. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007; 129:1311-1323.
18. Niinuma T, Suzuki H, Nojima M, Nosho K, Yamamoto H, Takamaru H, Yamamoto E, Maruyama R, Nobuoka T, Miyazaki Y. Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer research. 2012; 72:1126-1136.
19. Wang KC, Yang YW, Liu B, Sanyal A, Corces-Zimmerman R, Chen Y, Lajoie BR, Protacio A, Flynn RA, Gupta RA. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature. 2011; 472:120-124.
20. Quagliata L, Matter MS, Piscuoglio S, Arabi L, Ruiz C, Procino A, Kovac M, Moretti F, Makowska Z, Boldanova T. Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology. 2014; 59:911-923.
21. Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA biology. 2012; 9:703-719.
22. Wei P, Han B, Chen Y. Role of long non-coding RNAs in normal and malignant hematopoiesis. Science China Life Sciences. 2013; 56:867-875.
23. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai M-C, Hung T, Argani P, Rinn JL. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010; 464:1071-1076.
24. Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, Young G, Lucas AB, Ach R, Bruhn L. lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature. 2011; 477:295-300.
25. Zhang X, Lian Z, Padden C, Gerstein MB, Rozowsky J, Snyder M, Gingeras TR, Kapranov P, Weissman SM, Newburger PE. A myelopoiesis-associated regulatory intergenic noncoding RNA transcript within the human HOXA cluster. Blood. 2009; 113:2526-2534.
26. Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S, Löwenberg B, Delwel R, Valk PJ. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. haematologica. 2009; 94:131-134.
27. Network CGAR. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. The New England journal of medicine. 2013; 368:2059.
28. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland M-C, Heinecke A, Radmacher M, Marcucci G, Whitman SP. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008; 112:4193-4201.
29. Braekeleer ED, Douet-Guilbert N, Basinko A, Bris M-JL, Morel F, Braekeleer MD. Hox gene dysregulation in acute myeloid leukemia. Future Oncology. 2014; 10:475-495.
30. Thompson A, Quinn MF, Grimwade D, O'Neill CM, Ahmed MR, Grimes S, McMullin MF, Cotter F, Lappin TR. Global down-regulation of HOX gene expression in PMLRARα+ acute promyelocytic leukemia identified by smallarray real-time PCR. Blood. 2003; 101:1558-1565.
31. Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland M-C, Berdel WE, Büchner T. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. Journal of clinical oncology. 2010; 28:570-577.
32. Kohlmann A, Schoch C, Dugas M, Schnittger S, Hiddemann W, Kern W, Haferlach T. New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes. Leukemia. 2005; 19:953-964.
33. Camós M, Esteve J, Jares P, Colomer D, Rozman M, Villamor N, Costa D, Carrió A, Nomdedéu J, Montserrat E. Gene expression profiling of acute myeloid leukemia with translocation t (8; 16)(p11; p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer research. 2006; 66:6947-6954.
34. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE, van Galen JF, Beverloo HB, Sonneveld E, Kaspers G-JJ. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood. 2011; 118:3645-3656.
35. de Rooij J, Hollink I, Arentsen-Peters S, van Galen J, Beverloo HB, Baruchel A, Trka J, Reinhardt D, Sonneveld E, Zimmermann M. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia. 2013; 27:2280-2288.
36. Mullighan C, Kennedy A, Zhou X, Radtke I, Phillips L, Shurtleff S, Downing J. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia. 2007; 21:2000-2009.
37. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu Y-Z, Schwind S, Paschka P. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-and microRNAexpression signatures: a Cancer and Leukemia Group B study. Journal of clinical oncology. 2010; 28:596-604.
38. Sessa L, Breiling A, Lavorgna G, Silvestri L, Casari G, Orlando V. Noncoding RNA synthesis and loss of Polycomb group repression accompanies the colinear activation of the human HOXA cluster. Rna. 2007; 13:223-239.
39. Van Vlierberghe P, van Grotel M, Tchinda J, Lee C, Beverloo HB, van der Spek PJ, Stubbs A, Cools J, Nagata K, Fornerod M. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood. 2008; 111:4668-4680.
40. Alyea EP. Time to Reconsider the Role of Allogeneic Transplantation for Patients With Acute Myeloid Leukemia and NPM1 Mutation? Journal of clinical oncology. 2014: JCO. 2014.2058.6818.
41. Zhang X, Sun S, Pu JKS, Tsang ACO, Lee D, Man VOY, Lui WM, Wong STS, Leung GKK. Long non-coding RNA expression profiles predict clinical phenotypes in glioma. Neurobiology of disease. 2012; 48:1-8.
42. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011; 146:353-358.
43. Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014; 505:344-352.
44. Ulitsky I, Bartel DP. lincRNAs: genomics, evolution, and mechanisms. Cell. 2013; 154:26-46.
45. Zhang X, Weissman SM, Newburger PE. Long intergenic non-coding RNA HOTAIRM1 regulates cell cycle progression during myeloid maturation in NB4 human promyelocytic leukemia cells. RNA biology. 2014; 11:777-787.
46. Chen P, Price C, Li Z, Li Y, Cao D, Wiley A, He C, Gurbuxani S, Kunjamma RB, Huang H. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proceedings of the National Academy of Sciences. 2013; 110:11511-11516.
47. Havelange V, Garzon R. MicroRNAs: emerging key regulators of hematopoiesis. American journal of hematology. 2010; 85:935-942.
48. Rosa A, Ballarino M, Sorrentino A, Sthandier O, De Angelis F, Marchioni M, Masella B, Guarini A, Fatica A, Peschle C. The interplay between the master transcription factor PU. 1 and miR-424 regulates human monocyte/macrophage differentiation. Proceedings of the National Academy of Sciences. 2007; 104:19849-19854.
49. Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M, Paraskevopoulou MD, Prionidis K, Dalamagas T, Hatzigeorgiou AG. DIANA miRPath v. 2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic acids research. 2012; 40:W498-W504.
50. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. The Annals of Statistics. 1988; 16:1141-1154.
51. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. Journal of the American Statistical Association. 1999; 94:496-509.
52. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform. 2007; 3:11-17.
53. Breems DA, Van Putten WL, De Greef GE, Van ZelderenBhola SL, Gerssen-Schoorl KB, Mellink CH, Nieuwint A, Jotterand M, Hagemeijer A, Beverloo HB, Lowenberg B. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008; 26:4791-4797.